Trainings and Resources
28 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/14/2021 (updated 9/14/2022)
The Economic Research Service (ERS) at the U.S. Department of Agriculture details their research into contributing factors for geographic differences, with a focus on the widespread introduction of prescription drugs in rural and urban areas. See the Events section below to register for an ERS webinar on this report, taking place at 1:00 pm ET today.
Posted 3/16/2022 (updated 8/31/2022)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 6/9/2021 (updated 8/24/2022)
Since the beginning of the COVID-19 pandemic, its consequences have had a severe effect on mental health (Czeisler et al., 2020; Sher, 2020). Factors such as economic anxiety, social isolation due to necessary social distancing regulations, anxiety and fear regarding the virus, and chronic stress are factors that have contributed to the increase in mental health symptoms (Sher, 2020). Since the start of the pandemic, there have been notable increases in depression and anxiety and increased psychological distress in both the general population and among healthcare professionals (Sher, 2020). A large survey of adults in the U.S. found that there was a substantial increase in anxiety and depressive symptoms endorsed compared to the same time the previous year (Czeisler et al., 2020).
Posted 3/22/2022 (updated 8/17/2022)
Yesterday, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing two grant programs totaling $25.6 million that will expand access to medication-assisted treatment for opioid use disorder and prevent the misuse of prescription drugs. By reducing barriers to accessing the most effective, evidenced-based treatments, this funding reflects the priorities of HHS' Overdose Prevention Strategy, as well as its new initiative to strengthen the nation's mental health and crisis care systems.
Posted 3/24/2022 (updated 8/17/2022)
If you received specific disposal instructions from your healthcare provider (e.g., doctor, pharmacist) for your unused or expired medicine, you should follow those instructions to dispose of your medicine. The best disposal option is to find a drug take back location, which may be found in retail, hospital, or clinic pharmacies; and/or law enforcement facilities.
The U.S. Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing a State Opioid Response (SOR) grant funding opportunity that will provide nearly $1.5 billion to states and territories to help address the Nation’s opioid addiction and overdose epidemic. In President Biden’s State of the Union, he named beating the opioids epidemic as a pillar of his Unity Agenda. Today’s announcement is a critical step forward in that work, and the SOR program, along with the Tribal Opioid Response grant funding opportunity announced recently, are critical tools in President Biden’s inaugural National Drug Control Strategy released last month and the Health and Human Services’ (HHS) Overdose Prevention Strategy.
The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.
Posted 4/20/2022 (updated 5/6/2022)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 9/22/2021 (updated 10/1/2021)
IMPORTANCE Polysubstance use is a concern for patients treated for opioid use disorder (OUD). While buprenorphine can curtail harmful opioid use, co-occurring use of nonprescribed substances, such as cocaine, methamphetamine, and other opioids, may negatively affect treatment outcomes. OBJECTIVE To characterize factors associated with urine drug positivity for nonprescribed substances among patients prescribed buprenorphine